Blood test may predict kidney cancer drug response

NCT ID NCT03185039

Ongoing Knowledge-focused Sponsor: Institut Paoli-Calmettes Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is looking at two substances in the blood, called MMP2 and MMP9, to see if they can predict how well certain drugs work for people with advanced kidney cancer. Researchers will measure these markers in 50 patients who are starting treatment with Sunitinib or Pazopanib, and compare them to patients with localized or limited spread cancer not on these drugs. The goal is to find a simple blood test that helps doctors choose the best treatment for each patient.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors predict which kidney cancer patients will benefit from anti-angiogenic drugs like Sunitinib or Pazopanib.
What could go wrong: This is a small, early-stage biomarker study with only 50 participants. It does not test a new treatment, so it may not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney cancer renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY CANCER

Contacts and locations

Locations

Institut Paoli Calmettes

Marseille, 13009, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.